Biocon unveils India's first 24-hour diabetes drug

 
According to Biocon chief Kiran Mazumdar-Shaw, the product, Basalog, is the first diabetic drug whose effect lasts a full 24 hours.

She told presspersons here that the drug will be available in the Indian market from Saturday in 10 ml and 3 ml vials. Basalog is effective for both type one and type two diabetics, she added.

Shaw said diabetes is a debilitating disease, affecting global population like a pandemic.

Sadly India is the epicentre of the disease.

“Basalog is part of Biocon's commitment to provide best of diabetes management and care in India," the Biocon chief said.

According to her, Basalog ensures effective HbA1c control and has flexibility of injection timing, unlike other insulin. HbA1c is a diagnostic test to ascertain the patient's blood glucose level for a three-month period.

Statistics show that India has the largest diabetic population in the world with around 40 million people. Currently, there would be around 200-230 million diabetics in the world.

Mazumdar added that Biocon will be selling Basalog for 40 per cent less as compared to the present market price of some of the expensive insulin brands available in the market.

Rakesh Bamzai, president-marking, Biocon, said Biocon's research efforts over the years had yielded many important bio-therapeutics for diabetes and other life threatening
diseases.

DH Newsletter Privacy Policy Get top news in your inbox daily
GET IT
Comments (+)